SeaStar Medical Holding Corporation (ICU)
Nasdaq · Healthcare · Biotechnology
$3.55−24.31%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $15.6M
- 52-week range
- $2.07 – $7.35
- 52-week change
- −28.83%
- EPS (trailing)
- −$2.17
Fiscal year to Dec 2025
- Revenue
- $1.2M (+814.07%)
- Net income
- −$12.2M
- Operating margin
- −986.6%
From the company’s annual report on SEC EDGAR.
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Headquarters: Denver, United States · 18 employees · seastarmedical.com